Skip to main content

Advertisement

SpringerLink
Log in

Identification of urine PLK2 as a marker of bladder tumors by proteomic analysis

  • Original Article
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

Objective

To determine the patterns of urinary proteins in bladder cancer subjects using pooled urine from 27 bladder cancer patients.

Methods

The urine matrix was removed by acetonitrile precipitation followed by molecular weight cutoff. High performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry (HPLC–ESI-MS/MS) was used to analyze the urinary proteome. The candidate protein was validated by western blot.

Results

A total of 146 urinary proteins were identified. The protein list was screened using bioinformatic tools, and 11 cancer-related urinary proteins were found to be potential tumor markers for bladder cancer. However, only PLK2 was identified with high confidence. This candidate protein was validated by western blot using urine samples from 14 normal subjects and 10 bladder cancer patients. Statistically significant correlations were detected between PLK2 expression and bladder transitional cell carcinoma (TCC) (P < 0.05). Urinary PLK2 had a sensitivity of 80% at a specificity of 64% for bladder TCC in the samples tested.

Conclusions

Our results demonstrate overexpression of PLK2 in bladder carcinomas, suggesting a possible role of PLK2 in the pathogenesis of bladder carcinomas. However, the small cohort, preliminary results, and lack of subgroup analysis (such as carcinoma in situ, high grade, and stage) in this study prevent us from drawing definitive conclusions about the diagnostic value of PLK2 in these patients. Further studies directed toward a multitude of possible carcinogenic mechanisms of PLK2 in bladder cancer are warranted.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Vlahou H, Schellhammer PF, Mendrinos S et al (2001) Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. Am J Pathol 158:1491–1502

    CAS  PubMed  Google Scholar 

  2. Sarosdy MF, deVere White RW, Soloway MS (1995) Results of a multicenter trial using the BTA test to monitor for and diagnosis recurrent bladder cancer. J Urol 154:379–384

    Article  CAS  PubMed  Google Scholar 

  3. Sharms S, Zipper CD, Pandrangi L (1999) Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA test. J Urol 162:53–57

    Article  Google Scholar 

  4. Greence FL, Page DL, Fleming ID et al (eds) (2002) American Joint Committee on Cancer Staging manual, 6th edn. Springer, Philadelphia

  5. World Health Organization (1988) International histological classification of tumors, 2nd edn. World Health Organization, Geneva, 1969–1981, Springer, Berlin

  6. Tan LB, Chen KT, Tyan YC, Liao PC, Guo HR (2008) Proteomic analysis for human urinary proteins associated with arsenic intoxication. Proteomic Clin Appl 2:1087–1098

    Article  CAS  Google Scholar 

  7. Bradford MM (1976) A rapid and sensitive method for the quantitation of protein. Anal Biochem 72:248–254

    Article  CAS  PubMed  Google Scholar 

  8. Washburn MP, Wolters DA, Yates JR (2001) Large-scale analysis of the yeast proteome by multidimensional technology. Nat Biotechnol 19:242–247

    Article  CAS  PubMed  Google Scholar 

  9. Wang GY, Lu CQ, Zhang RM, Hu XH, Luo ZW (2008) The E-cadherin gene polymorphism 160C→A and cancer risk: a HuGE review and meta-analysis of 26 case–control studies. Am J Epidemiol 167:7–14

    Article  PubMed  Google Scholar 

  10. Kunzli BM, Berberat PO, Zhu ZW et al (2002) Influences of the lysosomal associated membrane proteins (Lamp-1, Lamp-2) and Mac-2 binding protein (Mac-2-BP) on the prognosis of pancreatic carcinoma. Cancer 94:228–239

    Article  CAS  PubMed  Google Scholar 

  11. Saitoh O, Wang WC, Lotan R, Fukuda M (1992) Differential glycosylation and cell surface expression of lysosomal membrane glycoproteins in sublines of a human colon cancer exhibiting distinct metastatic potentials. J Biol Chem 267:5700–5711

    CAS  PubMed  Google Scholar 

  12. Ang C, Chambers AF, Tuck AB, Winquist E, Izawa JI (2005) Plasma osteopontin levels are predictive of disease stage in patients with transitional cell carcinoma of the bladder. BJU Int 96:803–805

    Article  CAS  PubMed  Google Scholar 

  13. Deepak AG, Chen T, Irby R et al (2002) Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst 94:513–516

    Google Scholar 

  14. Tolson JP, Flad T, Gnau V et al (2006) Differential detection of S100A8 in transitional cell carcinoma of the bladder by pair wise tissue proteomic and immunohistochemical analysis. Proteomics 6:697–708

    Article  CAS  PubMed  Google Scholar 

  15. El-Rifai W, Moskaluk CA, Abdrabbo MK et al (2002) Gastric cancers overexpress S100A calcium-binding proteins. Cancer Res 62:6823–6826

    CAS  PubMed  Google Scholar 

  16. Yoon SY, Lee Y, Kim JH et al (2005) Over-expression of human UREB1 in colorectal cancer: HECT domain of human UREB1 inhibits the activity of tumor suppressor p53 protein. Biochem Biophys Res Commun 326:7–17

    Article  CAS  PubMed  Google Scholar 

  17. Wang Y, Han KJ, Pang XW et al (2002) Large scale identification of human hepatocellular carcinoma-associated antigens by autoantibodies. J Immunol 169:1102–1109

    CAS  PubMed  Google Scholar 

  18. Rudman D, Chawla RK, Wadsworth AD, Nixon DW, Schwartz M (1977) A system of cancer-related urinary glycoproteins: biochemical properties and clinical applications. Trans Assoc Am Physicians 90:286–299

    CAS  PubMed  Google Scholar 

  19. Chawla RK, Lawson DH, Ahmad M, Travis J (1992) Cancer-related urinary proteinase inhibitor, EDC1: a new method for its isolation and evidence for multiple forms. J Cell Biochem 50:227–236

    Article  CAS  PubMed  Google Scholar 

  20. Syed N, Smith P, Sullivan A et al (2006) Transcriptional silencing of Polo-like kinase 2 (SNK/PLK2) is a frequent event in B-cell malignancies. Blood 107:250–256

    Article  CAS  PubMed  Google Scholar 

  21. Ylagan LR, Scholes J, Demopoulos R (2000) CD 44: a marker of squamous differentiation in adenosquamous neoplasms. Arch Pathol Lab Med 124:212–215

    CAS  PubMed  Google Scholar 

  22. Miyake H, Hara I, Kamidono S, Eto H (2004) Multifocal transitional cell carcinoma of the bladder and upper urinary tract: molecular screening of clonal origin by characterizing CD44 alternative splicing patterns. J Urol 172:1127–1129

    Article  CAS  PubMed  Google Scholar 

  23. Koochekpour S, Zhuang YJ, Beroukhim R et al (2005) Amplification and overexpression of prosaposin in prostate cancer. Genes Chromosomes Cancer 44:351–364

    Article  CAS  PubMed  Google Scholar 

  24. Mukoyama Y, Zhou S, Miyachi Y, Matsuyoshi N (2005) T-cadherin negatively regulates the proliferation of cutaneous squamous carcinoma cells. J Invest Dermatol 124:833–838

    Article  CAS  PubMed  Google Scholar 

  25. Halachmi S, Linn JF, Amiel GE, Moskovitz B, Nativ O (1998) Urine cytology, tumour markers and bladder cancer. Brit J Urol 82:647–654

    CAS  PubMed  Google Scholar 

  26. Sphar CS, Davis MT, McGinley MD et al (2001) Towards defining the urinary proteome using liquid chromatography–tandem mass spectrometry. I. Profiling an unfractionated tryptic digest. Proteomics 1:93–107

    Article  Google Scholar 

  27. D’Assoro AB, Lingle L, Salisbury JL (2000) Centrosome amplification and the development of cancer. Oncogene 21:6146–6153

    Article  Google Scholar 

  28. Malumbres M, Barbacid M (2007) Cell cycle kinases in cancer. Curr Opin Genet Dev 17:60–65

    Article  CAS  PubMed  Google Scholar 

  29. Nigg E (2000) Centrosome aberrations: cause or consequence of cancer progression? Nat Rev Cancer 2:815–825

    Article  Google Scholar 

  30. Yamamoto Y, Matsuyama H, Kawauchi S et al (2006) Overexpression of Polo-like kinase 1 (PLK1) and chromosomal instability in bladder cancer. Oncology 70:231–237

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This work was partially supported by grants (NSC-94-2314-B-006-037) from the National Science Council.

Conflict of interest statement

There is no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Urology, St. Joseph Hospital, Huwei, Yunlin, Taiwan

    Lia-Beng Tan

  2. Department of Public Health, College of Medicine, National Cheng Kung University, Tainan, Taiwan

    Kow-Tong Chen

  3. Department of Environmental and Occupational Health, College of Medicine, National Cheng Kung University, 138 Sheng-Li Road, Tainan, Taiwan

    Lia-Beng Tan, Yu-Chang Yuan, Pao-Chi Liao & How-Ran Guo

Authors
  1. Lia-Beng Tan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kow-Tong Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yu-Chang Yuan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Pao-Chi Liao
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. How-Ran Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to How-Ran Guo.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tan, LB., Chen, KT., Yuan, YC. et al. Identification of urine PLK2 as a marker of bladder tumors by proteomic analysis. World J Urol 28, 117–122 (2010). https://doi.org/10.1007/s00345-009-0432-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-009-0432-y

Keywords

Search

Navigation